Korro Bio and Frequency Therapeutics Announce Merger Agreement | Press Release, Webcast
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency
Korro Bio Raises $116 Million for RNA Editing Program
Korro Bio sings to the tune of $116M for its OPERA RNA editing program
RNA-editing startup to double headcount with $116M in new VC
Development of a selection assay for small guide RNAs that drive efficient site-directed RNA editing